Clinical Trial Update: LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial evaluating LK101 in combination with a PD-1 or PD-L1 monoclonal antibody for lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• LK101
• PD-1/PD-L1 monoclonal antibody

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING